2m 2m 2m 2m 2m 2m 2m
Biogen (BIIB)
NASDAQ
$198.30-$0.37 (-0.19%)
Price as of Jun 18, 2026 4:33 AM EDT- $28.9BMarket Cap
- 57.00%1-Year Change
- Drug Manufacturers - GeneralIndustry
Biogen (BIIB)
$198.30-$0.37 (-0.19%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 7.1B -26.42% | 9.7B -1.62% | 9.8B -3.32% | 10.2B -7.36% | |
Cost of Revenue | 2.4B +4.06% | 2.3B -8.80% | 2.5B +11.20% | 2.3B +7.99% | |
Gross Profit | 4.7B -35.98% | 7.4B +0.87% | 7.3B -7.51% | 7.9B -11.01% | |
Sales and Marketing Expense | 2.4B +1.24% | 2.4B -5.73% | 2.5B +6.08% | 2.4B -10.12% | |
Research and Development Expense | -1.8B -12.89% | -2.0B -17.07% | -2.5B +10.35% | -2.2B -11.44% | |
Depreciation and Amortization Expense | 779.9M +15.85% | 673.2M +36.05% | 494.8M -4.55% | 518.4M +6.29% | |
Total Operating Expenses | 8.3B +7.26% | 7.8B -9.00% | 8.5B +29.74% | 6.6B -19.15% | |
Operating Profit | 1.6B -18.34% | 1.9B +46.98% | 1.3B -63.90% | 3.6B +26.44% | |
Interest Income | 125.0M +84.91% | 67.6M -75.55% | 276.5M +209.63% | 89.3M +711.82% | |
Interest Expense | -267.5M +6.87% | -250.3M +1.38% | -246.9M +0.12% | -246.6M -2.76% | |
Interest Income and Expense and Net | -142.5M -22.00% | -182.7M -717.23% | 29.6M +118.82% | -157.3M -35.16% | |
Total Nonoperating Income and Expense | -305.6M -11.06% | -343.6M +8.91% | -315.5M -391.59% | 108.2M +109.88% | |
Income before Taxes | 1.6B -18.34% | 1.9B +46.98% | 1.3B -63.90% | 3.6B +105.81% | |
Income Taxes | 263.6M -3.73% | 273.8M +102.37% | 135.3M -78.62% | 632.8M +1,105.33% | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | 1.3B -20.79% | 1.6B +40.57% | 1.2B -61.89% | 3.0B +95.80% | |
Net Income from Continuing Operations Applicable to Common | 1.6B -4.64% | 1.6B +40.57% | 1.2B -61.89% | 3.0B +95.80% | |
Basic EPS and Net Income | 8.83 -21.23% | 11.21 +39.78% | 8.02 -61.74% | 20.96 +100.77% | |
Diluted EPS and Net Income | 8.79 -21.38% | 11.18 +40.28% | 7.97 -61.81% | 20.87 +100.67% | |
Basic Weighted Average Shares | 146.5M +0.62% | 145.6M +0.62% | 144.7M -0.41% | 145.3M -2.55% | |
Diluted Weighted Average Shares | 147.1M +0.82% | 145.9M +0.21% | 145.6M -0.27% | 146.0M -2.41% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.0B +26.67% | 2.4B +126.21% | 1.0B -69.29% | 3.4B +51.20% | |
Short-Term Investments | 807.2M N/A | N/A N/A | 0 -100.00% | 1.5B -4.39% | |
Cash and Cash Equivalents and Short-Term Investments | 3.8B +60.66% | 2.4B +126.21% | 1.0B -78.54% | 4.9B +28.67% | |
Total Current Assets | 9.0B +20.35% | 7.5B +8.71% | 6.9B -29.94% | 9.8B +24.63% | |
Accumulated Depreciation | 2.9B +9.75% | 2.7B +11.17% | 2.4B +10.93% | 2.2B +7.93% | |
Property and Plant and Equipment and Net | 3.1B -3.96% | 3.2B -3.88% | 3.3B +0.34% | 3.3B -3.45% | |
Total Long-Term Assets | 750.6M +33.92% | 560.5M -24.77% | 745.0M -51.28% | 1.5B -21.15% | |
Total Assets | 29.4B +4.96% | 28.0B +4.49% | 26.8B +9.33% | 24.6B +2.83% | |
Income Taxes Payable | 622.4M -15.76% | 738.8M -17.84% | 899.2M +51.23% | 594.6M -31.59% | |
Total Short-Term Debt | 0 -100.00% | 1.7B +1,065.73% | 150.0M N/A | 0 -100.00% | |
Total Current Liabilities | 3.3B -39.42% | 5.5B +60.99% | 3.4B +4.93% | 3.3B -23.86% | |
Total Long-Term Debt | 6.3B +38.26% | 4.5B -33.01% | 6.8B +8.08% | 6.3B +0.11% | |
Total Long-Term Liabilities | 748.5M +2.21% | 732.3M -6.25% | 781.1M -17.27% | 944.2M -28.50% | |
Total Liabilities | 11.2B -1.33% | 11.3B -5.91% | 12.0B +7.88% | 11.2B -13.56% | |
Retained Earnings | 20.6B +6.71% | 19.3B +9.26% | 17.6B +7.05% | 16.5B +18.36% | |
Total Stockholders Equity | 18.3B +9.22% | 16.7B +12.95% | 14.8B +10.46% | 13.4B +22.96% | |
Total Shares Outstanding | 0 -100.00% | 145.8M +0.62% | 144.9M +0.63% | 144.0M -2.04% | |
Cash Flow | |||||
Cash from Operating Activities | 2.2B -23.33% | 2.9B +85.85% | 1.5B +11.77% | 1.4B -61.97% | |
Capital Expenditures | 153.8M +0.07% | 153.7M -44.51% | 277.0M +15.27% | 240.3M -6.90% | |
Cash from Investing Activities | -1.4B +71.56% | -799.2M -80.51% | -4.1B -360.12% | 1.6B +379.69% | |
Dividends Paid | 0 N/A | 0 -100.00% | 12.3M -0.81% | 12.4M +113.14% | |
Cash from Financing Activities | -301.9M -55.83% | -683.5M -557.80% | 149.3M +108.54% | -1.7B -16.24% | |
Financials Ratio | |||||
Gross Margin | 66.23% -12.99% | 76.12% +2.53% | 74.24% -4.33% | 77.61% -3.94% | |
Operating Margin | 21.86% +10.99% | 19.70% +49.40% | 13.18% -62.66% | 35.31% +36.49% | |
Return on Assets | 4.50% -24.36% | 5.95% +31.62% | 4.52% -64.09% | 12.58% +96.07% | |
Return on Equity | 7.39% -28.62% | 10.36% +25.77% | 8.24% -67.17% | 25.08% +74.06% | |
Revenue Growth | -26.42% +1,527.23% | -1.62% -51.10% | -3.32% -54.89% | -7.36% -59.82% | |
Current Ratio | 2.68 +98.66% | 1.35 -32.47% | 2.00 -33.24% | 2.99 +63.67% | |
Cash Ratio | 0.90 +109.08% | 0.43 +40.53% | 0.31 -70.74% | 1.04 +98.59% | |
Debt-to-Equity Ratio | 0.34 -8.55% | 0.38 -19.67% | 0.47 0.00% | 0.47 -29.77% | |
Debt-to-Assets Ratio | 0.21 -4.90% | 0.22 -13.15% | 0.26 +1.06% | 0.26 -16.02% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow